<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:"Palatino Linotype";
panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:308631315;
mso-list-template-ids:1541959166;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1
{mso-list-id:1299645646;
mso-list-template-ids:-340604598;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2
{mso-list-id:1591310646;
mso-list-template-ids:-929105592;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3
{mso-list-id:1958681274;
mso-list-template-ids:299509620;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:"Palatino Linotype",serif;color:#0070C0"><a href="https://med.fsu.edu/researchdivision/toffler-scholar-program">Toffler Scholar Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:"Palatino Linotype",serif">Open to FSU researchers</span></b><span style="font-size:12.0pt;font-family:"Palatino Linotype",serif">. The Toffler Scholar Program was created by the Trustees of
the Karen Toffler Charitable Trust, a 501 C3 nonprofit foundation focused on early-stage research that advances the medical field in profound, high-impact ways. Tapping into the deep legacy of their founders, best-selling authors and futurists, Alvin and Heidi
Toffler, the trust exists to be a catalyst for future – focused breakthroughs. The Toffler Scholar Program focuses on helping university medical researchers gain access to support, and a network for often underfunded innovations. It is a nimble source of financial
support for medical researchers working on <b>early-stage, future-focused brain science</b>. Together with the FSU College of Medicine, the program helps foster new ways of thinking and problem solving to find solutions to humanity’s most difficult problems.
Toffler Scholar grants are one-year grants that currently range from $20,000 - $30,000 per award.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:"Palatino Linotype",serif">Due November 9, 2020.</span></b><span style="font-size:12.0pt;font-family:"Palatino Linotype",serif">
<b><span style="color:red">Med-RA draft review is not required.</span></b><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:"Palatino Linotype",serif"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.fundacionmapfre.org/fundacion/en/grants-aids-and-awards/aids/ignacio-larramendi-research-grants/__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v6E6aKfEs$" target="_blank">Fundacion MAPFRE’s Ignacio H. de Larramendi Research
Grants: Health Promotion</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Open to researchers worldwide, the Fundacion MAPFRE is awarding
<b>Research Grants totaling 240,000 Euros</b> to provide financial support <b>for undertaking one-year research projects</b> in areas of
<b>Health Promotion</b>.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">The research projects</span></b><span style="font-size:12.0pt;font-family:Palatino"> will focus on
<b>Health Promotion</b>:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l3 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Strategies for habit change: prevention of obesity and promotion of physical activity.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Patient education.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Physical injury assessment.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Health management: clinical quality and safety.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Special attention will be given to the projects which, while taking into account the previous topic lines, incorporate aspects related to COVID-19 such as: reducing infections, self-care
and the culture of self-protection, relationship between previous health status (lifestyle) and morbimortality, COVID-19 and mental health, etc.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 30, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: October 19.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/pubs/2020/nsf20589/nsf20589.htm__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v6pHe2zG8$" target="_blank">NSF Division of Materials Research — Topical Materials Research Programs: Biomaterials (BMAT), Condensed Matter
Physics (CMP), Metals and Metallic Nanostructures (MMN), Polymers (POL) (DMR-TMRP BMAT, CMP, MMN, POL)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Research supported by the Division of Materials Research (DMR) focuses on advancing fundamental understanding of materials, materials discovery, design, synthesis, characterization, properties,
and materials-related phenomena. DMR awards enable understanding of the electronic, atomic, and molecular structures, mechanisms, and processes that govern nanoscale to macroscale morphology and properties; manipulation and control of these properties; discovery
of emerging phenomena of matter and materials; and creation of novel design, synthesis, and processing strategies that lead to new materials with unique characteristics. These discoveries and advancements transcend traditional scientific and engineering disciplines.
The Division supports research and education activities in the United States through funding of individual investigators, teams, centers, facilities, and instrumentation. Projects supported by DMR are essential for the development of future technologies and
industries that meet societal needs, as well preparation of the next generation of materials researchers. The
<b>Biomaterials program</b> supports <b>fundamental materials research</b> related to 1) biological materials, 2) biomimetic, bioinspired, and bioenabled materials, 3) synthetic materials intended for applications in contact with biological systems, and 4)
the processes through which nature produces biological materials. Projects are typically interdisciplinary and may encompass scales from the nanoscopic to the bulk. They may involve characterization, design, preparation, and modification; studies of structure-property
relationships and interfacial behavior; and combinations of experiment, theory, and/or simulation. Proposals involving biomaterials realized through synthetic biology; fueled biomaterials; stimuli-responsive biomaterials; antimicrobial or antiviral biomaterials;
biodegradable, renewable, and sustainable materials; and plant- or fungal- based biomaterials are also encouraged.
<b>The emphasis is on novel materials design and development, and discovery of new phenomena.
</b>Projects involving <i>in vitro</i> demonstration of biological compatibility and efficacy are appropriate, but the program can support only limited <i>in vivo</i> studies. Tissue engineering and drug/gene delivery projects must have a specific focus on
fundamental materials development and characterization. <o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 2, 2020 and November 1, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for 2020 due date: October 20.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/pubs/2021/nsf21506/nsf21506.htm__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v6I1WH9t8$" target="_blank">NSF Division of Integrative Organismal Systems Core Programs</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Division of Integrative Organismal Systems (IOS) Core Programs support research aimed at understanding why organisms are structured the way they are and function as they do. Proposals
are welcomed in all of the core scientific program areas supported by the Division of Integrative Organismal Systems (IOS). Areas of inquiry include, but are not limited to, developmental biology and the evolution of developmental processes, nervous system
development, structure, modification, function, and evolution; biomechanics and functional morphology, physiological processes, symbioses and microbial interactions, interactions of organisms with biotic and abiotic environments, plant and animal genomics,
and animal behavior. Proposals should focus on organisms as a fundamental unit of biological organization. Principal Investigators are encouraged to apply systems approaches that will lead to conceptual and theoretical insights and predictions about emergent
organismal properties.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">The clusters/programs in IOS which are participating in submissions to this solicitation are:</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l2 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=504676&org=IOS&from=home__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v6BG-L8Pc$">Behavioral Systems Cluster:</a> The Behavioral Systems cluster contains
the Animal Behavior Program.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=504677&org=IOS&from=home__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v6gUOancY$">Developmental Systems Cluster:</a> Programs within the Developmental
Systems Cluster are: the Plant, Fungal and Microbial Developmental Mechanisms Program, the Animal Developmental Mechanisms Program and the Evolution of Developmental Mechanisms Program.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=504678&org=IOS&from=home__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v68HwQJuQ$">Neural Systems Cluster:</a> Programs within the Neural Systems Cluster
are the Organization Program, the Activation Program and the Modulation Program.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=504679&org=IOS&from=home__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v6iTCJMJs$">Physiological and Structural Systems Cluster:</a> Programs within the
Physiological and Structural Systems Cluster are: the Symbiosis, Infection, and Immunity (SII) Program (formerly Symbiosis, Defense and Self-recognition), the Physiological Mechanisms and Biomechanics Program (PMB), the Integrative Ecological Physiology Program
(IEP) and the NSF-NIFA Plant Biotic Interactions Program (PBI).<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">The
<a href="https://urldefense.com/v3/__https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5338__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v61EwEhfA$" target="_blank" title="Plant Genome Research Program">
Plant Genome Research Program:</a> The Plant Genome Research Program (PGRP) supports genome-scale research and tool development to address challenging questions of biological, societal, and economic importance. Proposals intended for PGRP should be submitted
directly through its solicitation which can be found on the <a href="https://urldefense.com/v3/__https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5338__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v61EwEhfA$" title="PGRP program web page">
PGRP program web page</a> along with additional guidelines and current program contacts.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Applications welcome anytime.
<span style="color:red">Med-RA deadline to receive draft documents: Ten business days before submission.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-310.html__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v6Rg96YZg$" target="_blank">Health Services Research on Minority Health and Health Disparities (R01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative health services research that can directly and demonstrably contribute to the improvement of minority
health and/or the reduction of health disparities at the health care system-level as well as within clinical settings.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 27, 2020; March 17, 2021; November 17, 2021; March 17, 2022; November 17 2022; and February 17, 2023.
<span style="color:red">Note: November 27 is an FSU holiday; applications to this competition must be submitted by November 24. Med-RA deadline to receive draft documents for November 2020 due date: November 12.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.dkms.org/en/john-hansen-grant__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v663z3ktQ$" target="_blank">DKMS Foundation: John Hansen Research Grant–Study of Hematopoietic Stem Cell Transplantation and Cell Therapies in Hematologic
Malignancies</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.dkms.org/en__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v6QXFORT8$" target="_self">DKMS</a>, the world’s largest bone marrow donor center, invites young researchers to apply for one of the four scholarships awarded by
the DKMS Foundation for Giving Life through its John Hansen Research Grant program. Each of the four recipients of a Hansen grant will receive approximately $270,000 over a period of three years. The research should be in the field of stem cell therapy and
have the goal of sustainably and effectively supporting and advancing the fight against blood cancer. Various aspects may be covered, including but not restricted to transplant immunology, stem cell donation, cell manufacturing, as well as diagnostic and therapeutic
strategies. Applicants must have a doctoral degree that was awarded within the past eight years.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due December 8, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: November 23 (due to Thanksgiving holiday).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-046.html__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v66amuA8Q$" target="_blank">Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical
Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Through this Funding Opportunity Announcement, the National Cancer Institute intends to advance our understanding of: the modes of transmission of Kaposi sarcoma-associated herpesvirus
(KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and the risk factors for infection. Such studies should inform and advance efforts to reduce or eliminate KSHV transmission and thus prevent Kaposi sarcoma (KS),
KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of HIV infection.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due December 15, 2020 and December 14, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for December 2020 due date: December 2.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-21-027.html__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v6gGgWyNY$" target="_blank">Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets
(R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement seeks applications for comprehensive systems biology studies using multidisciplinary team science to identify common, overlapping etiologies of HIV-associated
comorbidities. Ultimately, the goal is to identify targets for intervention to mitigate multiple comorbidities associated with HIV infection.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 7, 2021; May 7, 2021; January 7, 2022; May 7, 2022; and January 7, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for January 2021 due date: December 14 (due to Winter Break).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Role of Myeloid Cells in Persistence and Eradication of HIV-1 Reservoirs from the Brain (R21 / R01 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/rfa-mh-20-702.html__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v6QXZrgqQ$" target="_blank">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-20-701.html__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v6UXsMY_o$" target="_blank">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These Funding Opportunity Announcements invite research grant applications studying mechanisms of HIV-1 persistence in myeloid cells and strategies to target this reservoir in the central
nervous system. Basic and translational research in domestic and international settings are of interest.
<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 8, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: December 14 (due to Winter Break).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-21-018.html__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v6-EJqEr0$" target="_blank">Using Syndemics to Understand HLBS Disease Emergence and Progression in People with HIV (PWH)(R01
Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement is intended to support research project grant (R01) applications that propose to utilize a syndemics (synergistic epidemic) framework to elucidate
the role of social, economic, environmental, behavioral, structural, psychological factors in promoting the synergistic interactions and clustering of heart, lung, blood, and sleep (HLBS) comorbidities among people with HIV at the population level. The ultimate
goal is to identify strategies that foster holistic approaches in the clinical management of people living with HIV who have HLBS comorbidities, and to utilize existing data to assess the feasibility and cost-effectiveness of such approaches.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 11, 2021 and December 14, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for January 2021 due date: December 15 (due to Winter Break).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-060.html__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v6G0rXyuQ$" target="_blank">Cohort Studies To Improve Our Understanding of Influenza Immunity, Vaccine Response and Effectiveness
in Older Adults (65 years and older) (U01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This initiative will support the use of longitudinal cohorts to develop greater understanding of important elements of influenza immunity that impact vaccine response and vaccine effectiveness
in older adults (those 65 and older). In addition, this work will increase our understanding of how these elements relate to severe outcomes from influenza virus infection in older adults (i.e., hospitalization and death).<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 4, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: January 25.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-301.html__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v6pX6Qzmo$" target="_blank">Drug Development Collaboratory (UG3 / UH3 Clinical Trial Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement is to support intramural-extramural collaborations on late-stage translational science projects between NCATS Therapeutic Development
Branch (TDB) and extramural researchers, for therapeutic development of small molecules, biologics, or gene therapies. The UG3 phase will provide support for late stage pre-clinical work and clinical trial planning that is conducted at applicant institutions.
The goal of any collaboration with TDB is to enable an IND application by the end of the UG3 phase. If UG3 milestones are met and an IND is cleared, support may be provided for an early stage clinical trials in the UH3 phase that will be conducted at the applicant
institutions.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 9, 2021; June 9, 2021; February 9, 2022; June 9, 2022; February 9, 2023; and June 9, 2023.<span style="color:red"> Med-RA deadline to receive draft documents for February
2021 due date: January 27.</span></span></b><span style="font-size:12.0pt;color:black"><o:p></o:p></span></p>
<p class="MsoNormal" style="caret-color: rgb(0, 0, 0);font-variant-caps: normal;orphans: auto;text-align:start;widows: auto;-webkit-text-size-adjust: auto;-webkit-text-stroke-width: 0px;word-spacing:0px">
<b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-055.html__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v6Rujrtr4$" target="_blank">Understanding Evolutionary Dynamics of Influenza to Inform and Improve Vaccine Strain
Selection (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The purpose of this Funding Opportunity Announcement is to support research to improve understanding of the evolutionary dynamics of seasonal influenza to increase our capacity
to predict the emergence of new antigenic variants and more accurately select strains for use in the seasonal influenza vaccine.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due February 11, 2021.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: February 1.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-057.html__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v6Yts86y0$" target="_blank">Understanding the Role of the M. Tuberculosis Granuloma in Tuberculosis (TB) Disease
and Treatment Outcomes (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">To support research to better define the role of the granuloma, the hallmark structure of pulmonary tuberculosis (TB), in TB disease and disease outcomes. Improved understanding
of the granuloma will provide a much-needed knowledge base for the development of improved therapeutic approaches.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due February 22, 2021.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: February 9.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-21-044.html__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v6Rm40BPE$" target="_blank">Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The Population Assessment of Tobacco and Health (PATH) Study provides the scientific community with biospecimens (urine, plasma, serum, and genomic DNA) and related research
data on behaviors, attitudes, biomarkers and health outcomes associated with tobacco use in the U.S. This opportunity allows investigators to apply for access to the biospecimens from the PATH Study. Information about the PATH Study and this resource may be
found on the <a href="https://urldefense.com/v3/__https://doi.org/10.3886/Series606__;!!PhOWcWs!guwwOpcMdCVZdPA9Q2kJrVlElZ31ka6Gcc9D7mGtx_3UQMfOteQXd31gErM-UreBA_nwhqr5y6v6pa9H-9M$">PATH Study series page</a> at the University of Michigan’s National Addiction & HIV Data Archive Program website, part of the Inter-University Consortium for Political and Social Research’s website.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due April 30, 2021; October 29, 2021; April 29, 2022; October 31, 2022; April 28, 2023; and October 31, 2023.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for April 2021 due date: April 19.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal" style="caret-color: rgb(0, 0, 0);font-variant-caps: normal;orphans: auto;text-align:start;widows: auto;-webkit-text-size-adjust: auto;-webkit-text-stroke-width: 0px;word-spacing:0px">
<b><span style="font-size:12.0pt;font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b>CoM’s
unofficial funding opportunities blog</b></a><b>.</b></span><span style="font-size:12.0pt;color:black"><o:p></o:p></span></p>
</div>
</body>
</html>